Theriva Net Receivables vs Other Current Liab Analysis

TOVX Stock

USD 1.18 0.01 0.84%

Theriva Biologics financial indicator trend analysis is much more than just breaking down Theriva Biologics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Theriva Biologics is a good investment. Please check the relationship between Theriva Biologics Net Receivables and its Other Current Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theriva Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.

Net Receivables vs Other Current Liab

Net Receivables vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Theriva Biologics Net Receivables account and Other Current Liab. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Theriva Biologics' Net Receivables and Other Current Liab is -0.09. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Theriva Biologics, assuming nothing else is changed. The correlation between historical values of Theriva Biologics' Net Receivables and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Theriva Biologics are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Net Receivables i.e., Theriva Biologics' Net Receivables and Other Current Liab go up and down completely randomly.

Correlation Coefficient

-0.09

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Receivables

Other Current Liab

Most indicators from Theriva Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Theriva Biologics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theriva Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.At this time, Theriva Biologics' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.75 in 2024, whereas Selling General Administrative is likely to drop slightly above 7.1 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	14.3M	21.6M	21.4M	13.9M
Cost Of Revenue	87K	268K	135K	183.7K

Total Operating Expenses Cost Of Revenue

Theriva Biologics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Other Stockholder Equity	Total Liab	Total Current Assets	Other Current Liab	Property Plant And Equipment Net	Non Currrent Assets Other	Inventory	Other Current Assets	Short Long Term Debt Total	Short Term Debt	Net Receivables	Non Current Liabilities Total	Short Term Investments	Intangible Assets	Common Stock	Common Stock Shares Outstanding	Good Will
Total Assets		0.14	0.94	-0.83	-0.76	0.01	0.79	0.73	0.79	0.86	0.46	0.81	0.12	0.84	-0.51	-0.76	0.54	0.9	0.48	0.46	0.53	-0.35	0.36	-0.27	0.51	0.71
Total Current Liabilities	0.14		-0.14	-0.14	-0.2	0.74	0.14	0.0	0.14	0.16	0.79	0.21	0.99	0.15	-0.13	0.06	0.33	0.04	0.04	-0.07	0.11	-0.28	0.27	0.09	-0.13	-0.01
Total Stockholder Equity	0.94	-0.14		-0.84	-0.68	-0.18	0.82	0.62	0.82	0.79	0.13	0.81	-0.15	0.72	-0.44	-0.76	0.4	0.82	0.38	0.39	0.33	-0.29	0.29	-0.3	0.63	0.61
Net Debt	-0.83	-0.14	-0.84		0.56	-0.01	-0.99	-0.23	-0.99	-0.64	-0.23	-0.98	-0.13	-0.5	0.39	0.55	-0.26	-0.56	0.0	0.01	-0.19	0.32	-0.32	0.06	-0.79	-0.21
Retained Earnings	-0.76	-0.2	-0.68	0.56		-0.16	-0.54	-0.64	-0.54	-0.98	-0.51	-0.55	-0.14	-0.84	0.35	0.83	-0.63	-0.74	-0.53	-0.49	-0.53	0.52	-0.52	0.49	-0.38	-0.62
Accounts Payable	0.01	0.74	-0.18	-0.01	-0.16		0.01	-0.13	0.01	0.1	0.55	0.1	0.64	0.03	0.0	0.16	0.24	-0.12	-0.1	-0.15	0.01	-0.23	0.24	-0.02	-0.14	-0.14
Cash	0.79	0.14	0.82	-0.99	-0.54	0.01		0.19	1.0	0.61	0.2	0.99	0.14	0.45	-0.41	-0.53	0.21	0.53	0.0	-0.07	0.16	-0.32	0.3	-0.05	0.78	0.17
Non Current Assets Total	0.73	0.0	0.62	-0.23	-0.64	-0.13	0.19		0.19	0.71	0.48	0.21	-0.02	0.85	-0.45	-0.66	0.59	0.88	0.85	0.8	0.73	-0.2	0.21	-0.39	-0.07	1.0
Cash And Short Term Investments	0.79	0.14	0.82	-0.99	-0.54	0.01	1.0	0.19		0.61	0.2	0.99	0.14	0.45	-0.41	-0.53	0.21	0.53	0.0	-0.07	0.16	-0.32	0.3	-0.05	0.78	0.17
Other Stockholder Equity	0.86	0.16	0.79	-0.64	-0.98	0.1	0.61	0.71	0.61		0.5	0.61	0.1	0.89	-0.38	-0.86	0.65	0.82	0.55	0.54	0.56	-0.49	0.5	-0.47	0.44	0.68
Total Liab	0.46	0.79	0.13	-0.23	-0.51	0.55	0.2	0.48	0.2	0.5		0.25	0.77	0.57	-0.33	-0.26	0.56	0.45	0.4	0.3	0.69	-0.32	0.33	-0.05	-0.14	0.47
Total Current Assets	0.81	0.21	0.81	-0.98	-0.55	0.1	0.99	0.21	0.99	0.61	0.25		0.2	0.46	-0.42	-0.53	0.25	0.54	0.03	-0.05	0.16	-0.35	0.33	-0.07	0.75	0.19
Other Current Liab	0.12	0.99	-0.15	-0.13	-0.14	0.64	0.14	-0.02	0.14	0.1	0.77	0.2		0.12	-0.12	0.08	0.3	0.02	0.01	-0.09	0.09	-0.25	0.24	0.13	-0.13	-0.03
Property Plant And Equipment Net	0.84	0.15	0.72	-0.5	-0.84	0.03	0.45	0.85	0.45	0.89	0.57	0.46	0.12		-0.27	-0.74	0.64	0.92	0.71	0.76	0.7	-0.32	0.33	-0.3	0.31	0.83
Non Currrent Assets Other	-0.51	-0.13	-0.44	0.39	0.35	0.0	-0.41	-0.45	-0.41	-0.38	-0.33	-0.42	-0.12	-0.27		0.4	0.04	-0.33	-0.16	0.12	-0.42	0.09	-0.09	0.2	0.03	-0.46
Inventory	-0.76	0.06	-0.76	0.55	0.83	0.16	-0.53	-0.66	-0.53	-0.86	-0.26	-0.53	0.08	-0.74	0.4		-0.42	-0.76	-0.52	-0.56	-0.44	0.42	-0.42	0.43	-0.49	-0.65
Other Current Assets	0.54	0.33	0.4	-0.26	-0.63	0.24	0.21	0.59	0.21	0.65	0.56	0.25	0.3	0.64	0.04	-0.42		0.66	0.6	0.6	0.45	-0.59	0.61	-0.51	-0.02	0.56
Short Long Term Debt Total	0.9	0.04	0.82	-0.56	-0.74	-0.12	0.53	0.88	0.53	0.82	0.45	0.54	0.02	0.92	-0.33	-0.76	0.66		0.77	0.75	0.63	-0.44	0.43	-0.42	0.31	0.86
Short Term Debt	0.48	0.04	0.38	0.0	-0.53	-0.1	0.0	0.85	0.0	0.55	0.4	0.03	0.01	0.71	-0.16	-0.52	0.6	0.77		0.84	0.59	-0.29	0.21	-0.41	-0.22	0.85
Net Receivables	0.46	-0.07	0.39	0.01	-0.49	-0.15	-0.07	0.8	-0.07	0.54	0.3	-0.05	-0.09	0.76	0.12	-0.56	0.6	0.75	0.84		0.49	-0.2	0.22	-0.34	-0.03	0.8
Non Current Liabilities Total	0.53	0.11	0.33	-0.19	-0.53	0.01	0.16	0.73	0.16	0.56	0.69	0.16	0.09	0.7	-0.42	-0.44	0.45	0.63	0.59	0.49		-0.13	0.13	-0.09	-0.09	0.72
Short Term Investments	-0.35	-0.28	-0.29	0.32	0.52	-0.23	-0.32	-0.2	-0.32	-0.49	-0.32	-0.35	-0.25	-0.32	0.09	0.42	-0.59	-0.44	-0.29	-0.2	-0.13		-0.98	0.8	-0.11	-0.17
Intangible Assets	0.36	0.27	0.29	-0.32	-0.52	0.24	0.3	0.21	0.3	0.5	0.33	0.33	0.24	0.33	-0.09	-0.42	0.61	0.43	0.21	0.22	0.13	-0.98		-0.81	0.12	0.18
Common Stock	-0.27	0.09	-0.3	0.06	0.49	-0.02	-0.05	-0.39	-0.05	-0.47	-0.05	-0.07	0.13	-0.3	0.2	0.43	-0.51	-0.42	-0.41	-0.34	-0.09	0.8	-0.81		0.15	-0.38
Common Stock Shares Outstanding	0.51	-0.13	0.63	-0.79	-0.38	-0.14	0.78	-0.07	0.78	0.44	-0.14	0.75	-0.13	0.31	0.03	-0.49	-0.02	0.31	-0.22	-0.03	-0.09	-0.11	0.12	0.15		-0.09
Good Will	0.71	-0.01	0.61	-0.21	-0.62	-0.14	0.17	1.0	0.17	0.68	0.47	0.19	-0.03	0.83	-0.46	-0.65	0.56	0.86	0.85	0.8	0.72	-0.17	0.18	-0.38	-0.09

Click cells to compare fundamentals

Theriva Biologics Account Relationship Matchups

Theriva Biologics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	17.2M	8.4M	70.4M	71.9M	55.2M	58.0M
Total Current Liabilities	5.3M	3.0M	3.6M	7.1M	6.7M	4.2M
Total Stockholder Equity	14.4M	8.0M	65.4M	54.6M	39.7M	41.7M
Net Debt	(14.3M)	(5.8M)	(65.8M)	(40.1M)	(21.0M)	(20.0M)
Retained Earnings	(235.5M)	(248.1M)	(271.3M)	(291.0M)	(309.3M)	(293.9M)
Accounts Payable	2.3M	886K	524K	915K	770K	1.1M
Cash	15.0M	6.2M	67.3M	41.8M	23.2M	12.9M
Non Current Assets Total	809K	476K	1.5M	26.3M	27.8M	29.2M
Cash And Short Term Investments	15.0M	6.2M	67.3M	41.8M	23.2M	13.0M
Liabilities And Stockholders Equity	17.2M	8.4M	70.4M	71.9M	55.2M	58.0M
Other Stockholder Equity	232.6M	240.8M	336.6M	343.5M	346.2M	363.5M
Total Liab	5.7M	3.2M	5.0M	17.3M	15.5M	16.3M
Total Current Assets	16.4M	7.9M	68.9M	45.5M	27.4M	14.4M
Other Current Liab	2.7M	1.8M	2.9M	5.7M	4.9M	3.0M
Property Plant And Equipment Net	786K	453K	1.5M	1.5M	2.2M	2.3M
Non Current Liabilities Total	473K	186K	1.4M	10.2M	8.8M	9.2M
Common Stock	17K	29K	132K	16K	18K	17.1K
Common Stock Shares Outstanding	1.6M	1.9M	12.2M	613.1K	644.3K	1.1M
Net Tangible Assets	(2.9M)	(7.2M)	65.4M	46.3M	53.3M	55.9M
Net Invested Capital	(2.9M)	(7.2M)	65.4M	52.1M	37.2M	28.6M
Capital Stock	17.3M	15.3M	132K	2.8M	2.8M	2.6M
Net Working Capital	11.2M	5.0M	65.3M	38.5M	20.7M	30.6M
Property Plant Equipment	786K	453K	1.5M	1.5M	1.8M	1.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Theriva Net Receivables vs Other Current Liab Analysis

Net Receivables vs Other Current Liab

Net Receivables vs Other Current Liab Correlation Analysis

Correlation Coefficient

Net Receivables

Other Current Liab

Theriva Biologics fundamental ratios Correlations

Theriva Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Theriva Biologics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Theriva Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Good Will	+ 1.0	Non Current Assets Total
Other Current Liab	+ 0.99	Total Current Liabilities
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Stockholder Equity	+ 0.94	Total Assets

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Intangible Assets	- 0.98	Short Term Investments
Other Stockholder Equity	- 0.98	Retained Earnings
Total Current Assets	- 0.98	Net Debt
Inventory	- 0.86	Other Stockholder Equity